Literature DB >> 23192314

Reduction in phencyclidine induced sensorimotor gating deficits in the rat following increased system xc⁻ activity in the medial prefrontal cortex.

Victoria Lutgen1, Krista Qualmann, Jon Resch, Linghai Kong, Sujean Choi, David A Baker.   

Abstract

RATIONALE: Aspects of schizophrenia, including deficits in sensorimotor gating, have been linked to glutamate dysfunction and/or oxidative stress in the prefrontal cortex. System xc(-), a cystine-glutamate antiporter, is a poorly understood mechanism that contributes to both cellular antioxidant capacity and glutamate homeostasis.
OBJECTIVES: Our goal was to determine whether increased system xc(-) activity within the prefrontal cortex would normalize a rodent measure of sensorimotor gating.
METHODS: In situ hybridization was used to map messenger RNA (mRNA) expression of xCT, the active subunit of system xc(-), in the prefrontal cortex. Prepulse inhibition was used to measure sensorimotor gating; deficits in prepulse inhibition were produced using phencyclidine (0.3-3 mg/kg, sc). N-Acetylcysteine (10-100 μM) and the system xc(-) inhibitor (S)-4-carboxyphenylglycine (CPG, 0.5 μM) were used to increase and decrease system xc(-) activity, respectively. The uptake of (14)C-cystine into tissue punches obtained from the prefrontal cortex was used to assay system xc(-) activity.
RESULTS: The expression of xCT mRNA in the prefrontal cortex was most prominent in a lateral band spanning primarily the prelimbic cortex. Although phencyclidine did not alter the uptake of (14)C-cystine in prefrontal cortical tissue punches, intraprefrontal cortical infusion of N-acetylcysteine (10-100 μM) significantly reduced phencyclidine- (1.5 mg/kg, sc) induced deficits in prepulse inhibition. N-Acetylcysteine was without effect when coinfused with CPG (0.5 μM), indicating an involvement of system xc(-).
CONCLUSIONS: These results indicate that phencyclidine disrupts sensorimotor gating through system xc(-) independent mechanisms, but that increasing cystine-glutamate exchange in the prefrontal cortex is sufficient to reduce behavioral deficits produced by phencyclidine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192314      PMCID: PMC3595356          DOI: 10.1007/s00213-012-2926-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  79 in total

1.  Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

Authors:  K Q Do; A H Trabesinger; M Kirsten-Krüger; C J Lauer; U Dydak; D Hell; F Holsboer; P Boesiger; M Cuénod
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

2.  SNARE protein-dependent glutamate release from astrocytes.

Authors:  A Araque; N Li; R T Doyle; P G Haydon
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

3.  Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia.

Authors:  L A Glantz; D A Lewis
Journal:  Arch Gen Psychiatry       Date:  2000-01

Review 4.  Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia.

Authors:  W E Bunney; B G Bunney
Journal:  Brain Res Brain Res Rev       Date:  2000-03

Review 5.  Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review.

Authors:  M A Geyer; K Krebs-Thomson; D L Braff; N R Swerdlow
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

Review 6.  Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges.

Authors:  N R Swerdlow; M A Geyer; D L Braff
Journal:  Psychopharmacology (Berl)       Date:  2001-07       Impact factor: 4.530

7.  Activation of group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulata.

Authors:  M J Marino; M Wittmann; S R Bradley; G W Hubert; Y Smith; P J Conn
Journal:  J Neurosci       Date:  2001-09-15       Impact factor: 6.167

8.  Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate.

Authors:  D V Pow
Journal:  Glia       Date:  2001-04-01       Impact factor: 7.452

9.  Effects of typical and atypical antipsychotics on the prepulse inhibition of the startle reflex in patients with schizophrenia.

Authors:  Bob Oranje; Clarine J Van Oel; Christine C Gispen-De Wied; Marinus N Verbaten; René S Kahn
Journal:  J Clin Psychopharmacol       Date:  2002-08       Impact factor: 3.153

10.  Cytosolic calcium oscillations in astrocytes may regulate exocytotic release of glutamate.

Authors:  L Pasti; M Zonta; T Pozzan; S Vicini; G Carmignoto
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

View more
  7 in total

Review 1.  Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Authors:  Kim Q Do; Michel Cuenod; Takao K Hensch
Journal:  Schizophr Bull       Date:  2015-06-01       Impact factor: 9.306

2.  Pituitary Adenylate cyclase-activating polypeptide orchestrates neuronal regulation of the astrocytic glutamate-releasing mechanism system xc (.).

Authors:  Linghai Kong; Rebecca Albano; Aric Madayag; Nicholas Raddatz; John R Mantsch; SuJean Choi; Doug Lobner; David A Baker
Journal:  J Neurochem       Date:  2016-03-01       Impact factor: 5.372

Review 3.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

4.  Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression.

Authors:  Mina G Nashed; Robert G Ungard; Kimberly Young; Natalie J Zacal; Eric P Seidlitz; Jennifer Fazzari; Benicio N Frey; Gurmit Singh
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

5.  Antioxidant Treatment with N-acetyl Cysteine Prevents the Development of Cognitive and Social Behavioral Deficits that Result from Perinatal Ketamine Treatment.

Authors:  Aarron Phensy; Hasmik E Duzdabanian; Samantha Brewer; Anurag Panjabi; Christopher Driskill; Annuska Berz; George Peng; Sven Kroener
Journal:  Front Behav Neurosci       Date:  2017-06-06       Impact factor: 3.558

6.  Functional effects of TrkA inhibition on system xC--mediated glutamate release and cancer-induced bone pain.

Authors:  Tanya Miladinovic; Robert G Ungard; Katja Linher-Melville; Snezana Popovic; Gurmit Singh
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

Review 7.  The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy.

Authors:  Vidyasagar Naik Bukke; Moola Archana; Rosanna Villani; Antonino Davide Romano; Agata Wawrzyniak; Krzysztof Balawender; Stanislaw Orkisz; Sarah Beggiato; Gaetano Serviddio; Tommaso Cassano
Journal:  Int J Mol Sci       Date:  2020-10-09       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.